Evidence map›Paper›PMID 40539104›Full record

ReviewFrontiers in microbiology2025

Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy.

Quan Wang, Rui Cao, Yuxing Xie, Zhuoyi Zhang, Xianguo Li, Yan Zhang, Haolin Luo, Hui Yao, Ping Xue, Shuai Ni

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Quan Wang *School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Rui Cao *Department of Anesthesiology, People's Hospital of Xinzhou, Wuhan, China.
Yuxing XieSchool of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Zhuoyi ZhangSchool of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Xianguo LiSchool of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Yan ZhangDepartment of Anesthesiology, Yunxi People's Hospital, Shiyan, China.
Haolin LuoGuangdong Provincial Key Laboratory for Plant Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China.
Hui YaoSchool of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Ping XueSchool of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Shuai NiDepartment of Neurosurgery, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotoxins (ITs), as targeted cancer therapies, confront limitations including off-target effects, immunogenicity, and inadequate tumor penetration, hindering clinical translation. Advances in tumor microenvironment (TME) understanding and genetic engineering have enabled engineered microorganisms such as attenuated

Indexed as

cancer therapycircuitsengineered microbesimmunotoxintumor penetration

Identifiers

PMID40539104
PMCPMC12177715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.